Small molecule · developed by Myriad Therapeutics
MPC-2130 is a small molecule that induces apoptosis in tumor cells, with effects including phosphatidylserine externalization, cytochrome C release from mitochondria, caspase activation and DNA fragmentation. It is not a substrate for several multidrug resistance efflux transporters, and is being studied in cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00387153 | Phase 1 | Cancer | Terminated | MYGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the MYGN page.
See MYGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MYGN catalysts and pipeline →